Form 4: Illumina SVP, General Counsel Charles Dadswell Reports Acquisition of Restricted Stock Units and Performance Shares

Charles Dadswell, SVP, General Counsel of Illumina, Inc., reported the acquisition of restricted stock units and performance shares on March 5, 2024, according to a Form 4 filing with the SEC.

Summary

• On March 5, 2024, Charles Dadswell, the SVP, General Counsel of Illumina, Inc., reported transactions involving the company's stock.
• Dadswell acquired 6,683 shares of common stock through restricted stock units, which will vest in installments from February 15, 2025, to February 15, 2028.
• He also acquired 7,797 performance shares tied to Illumina's three-year average operating margin for fiscal years 2024-2026, vesting on January 3, 2027.
• Additionally, Dadswell acquired 7,797 performance shares linked to Illumina's relative total shareholder return for the fiscal year ending January 3, 2027, also vesting on January 3, 2027.
• The number of shares issued for both types of performance stock units will range from 0% to 200% of the specified amount, based on the company's performance relative to pre-defined objectives.
• Following these transactions, Dadswell directly owns 7,797 performance shares and indirectly owns 22,298 shares of common stock through The Charles Dadswell Trust, which includes 132 shares acquired through the Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard executive compensation practices and aligns management's interests with the company's performance. The performance-based vesting of some shares is a positive incentive.

Positives

• The acquisition of restricted stock units and performance shares aligns Charles Dadswell's interests with the long-term performance of Illumina.
• The vesting schedules for the restricted stock units and performance shares encourage continued service and commitment to the company.
• The performance-based vesting of some shares incentivizes improved operating margin and shareholder return.

Risks

• The value of the restricted stock units and performance shares is subject to the performance of Illumina's stock price.
• The actual number of performance shares issued will depend on the company's performance against pre-defined objectives, which may not be met.
• The vesting of the awards is contingent upon Dadswell's continued service as a service provider.

Future Outlook

The number of performance shares ultimately vesting depends on Illumina's future financial performance, specifically its three-year average operating margin and relative total shareholder return.

Industry Context

This filing reflects standard executive compensation practices in the biotechnology industry, where stock-based awards are commonly used to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Companies like Thermo Fisher Scientific and Danaher also utilize performance-based equity awards to incentivize executives.
• The vesting schedules and performance metrics used by Illumina are generally consistent with industry norms.
• The percentage of equity compensation tied to performance metrics is a common practice to drive specific strategic goals.

Stakeholder Impact

• Shareholders may view the granting of performance-based equity awards as a positive sign, as it aligns management's interests with long-term value creation.
• Employees may be motivated by the potential for increased company performance and shareholder value.

Key Dates